Results 11 to 20 of about 126,909 (281)

Cardiac myosin inhibitors: a silver lining for an old disease [PDF]

Open Heart
Sandeep Singh, Sourabh Agstam, Satyavir Yadav   +2 more
doaj   +3 more sources

The Efficacy of Cardiac Myosin Inhibitors Versus Placebo in Patients with Symptomatic Hypertrophic Cardiomyopathy

Translation, 2023
Please view the PDF to see the formatted meeting abstract.  
Mohammand Yassen
doaj   +2 more sources

Efficacy and safety of myosin inhibitors for symptomatic hypertrophic cardiomyopathy: systematic review and meta-analysis [PDF]

Archives of Medical Science: Atherosclerotic Diseases
Introduction Hypertrophic cardiomyopathy (HCM) is a common genetic cardiac disorder associated with significant morbidity and mortality. Cardiac myosin inhibitors (MIs), including mavacamten and aficamten, offer a novel therapeutic approach for HCM ...
Mohammad Hazique, Sameer Lohana, Sunam Kafle, Jasgit Bhinder, Kunal N. Patel, Jawad Basit, Abdul Rasheed Bahar, Jared Kvapil, M. Chadi Alraies   +8 more
doaj   +2 more sources

Cardiac myosin inhibitors for hypertrophic cardiomyopathy: shedding light on their clinical potential

Expert Opinion on Investigational Drugs, 2023
Department of Medicine, MedStar Union Memorial Hospital, Baltimore, MD, USA; Department of Medicine, Creighton University Arizona Health Education Alliance, Phoenix, Az, USA; Tufts University School of Medicine, Boston, MA, USA; Department of Cardiology,
Shiavax J. Rao, Beani Forst, Amreen K Kanwal, Arjun Kanwal, W. Aronow, S. Naidu   +5 more
semanticscholar   +3 more sources

A New Era in the Management of Hypertrophic Cardiomyopathy [PDF]

Reviews in Cardiovascular Medicine
Hypertrophic cardiomyopathy (HCM) is a prevalent cardiac disease characterized by marked phenotypic variability. Recent advances in diagnosis and treatment have allowed a personalized approach to the treatment of this disease.
Ana Perez-Asensio, Helena Llamas-Gomez, Ana Lara-Palomo, Alberto Villar-Ruiz, Cesar Jimenez-Mendez, Julian Palomino-Doza   +5 more
doaj   +2 more sources

Coexistence of Hypertrophic Cardiomyopathy and Arterial Hypertension: Current Insights and Future Directions [PDF]

Diseases
Background: Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease. Arterial hypertension represents the leading modifiable risk factor for cardiovascular morbidity and mortality globally.
Vasiliki Katsi, Konstantia Papadomarkaki, Konstantinos Manousiadis, Epameinondas Triantafyllou, Christos Fragoulis, Konstantinos Tsioufis   +5 more
doaj   +2 more sources

A New Chapter in the Management of Hypertrophic Cardiomyopathy: Cardiac Myosin Inhibitors

Cardiologia Hungarica, 2023
In the recent years, there has been a significant breakthrough in the treatment of hypertrophic cardiomyopathy. New precision molecules have been developed and successfully applied in clinical trials. A new class of orally available allosteric inhibitors
E. Pálinkás, R. Sepp, I. Olivotto
semanticscholar   +3 more sources

Comprehensive Review: Mavacamten and Aficamten in Hypertrophic Cardiomyopathy [PDF]

Biomedicines
Hypertrophic cardiomyopathy (HCM) is the most common monogenic heart disease, with an estimated prevalence of 1:600 in the general population, and is associated with significant morbidity.
Helin Savsin, Tomasz Tokarek
doaj   +2 more sources

Myosin Modulator Aficamten Inhibits Force by Altering Myosin’s Biochemical Activity Without Changing Thick Filament Structure [PDF]

JACC: Basic to Translational Science
Summary: We investigated the effects of aficamten on cardiac muscle structure, biochemical activity, and contractile function. Aficamten does not structurally sequester myosin heads along the thick filament.
Saffie Mohran, PhD, Kristina B. Kooiker, PhD, Ateeqa Naim, BS, Matvey Pilagov, BS, Anthony Asencio, BS, Kyrah L. Turner, BS, Weikang Ma, PhD, Galina Flint, MD., Siyao Jiang, BS, Jing Zhao, BS, Timothy S. McMillen, PhD, Christian Mandrycky, PhD, Max Mahoney-Schaefer, BS, Thomas C. Irving, PhD, Bertrand C.W. Tanner, PhD, Neil M. Kad, PhD, Michael Regnier, PhD, Farid Moussavi-Harami, MD   +17 more
doaj   +2 more sources

A therapeutic leap: how myosin inhibitors moved from cardiac interventions to skeletal muscle myopathy solutions

The Journal of Clinical Investigation
The myosin inhibitor mavacamten has transformed the management of obstructive hypertrophic cardiomyopathy (HCM) by targeting myosin ATPase activity to mitigate cardiac hypercontractility.
Julius Bogomolovas, Ju Chen
doaj   +2 more sources